Bafna to launch olmesartan in Sri Lanka
This article was originally published in Scrip
Executive Summary
Bafna Pharmaceuticals of India is planning to launch the antihypertensive olmesartan medoxomil (branded as Olmebaf) in Sri Lanka early next year. The company expects to sell the product directly through its own front-end there. Olmesartan medoxomil and its combination with hydrochlorothiazide have been approved by the Drugs Controller General of India since 2005. Bafna said that the incidence of ischaemic heart disease and cerebrovascular disease in Sri Lanka has been on the rise over the past four decades and is similar to that of the developed world. The company has applied for registration of its product in a few more Asian countries. Chennai-based Bafna manufactures pharmaceutical formulations of betalactum and non–betalactum products and has more than 65 products registered in Sri Lanka, Ukraine, Laos and Ghana.
You may also be interested in...
How Sanofi Is ‘Playing To Win’ In India, Watch Diabetes Space
Sanofi India managing director Rodolfo Hrosz talks to Scrip about the company’s refreshed India strategy including in the competitive diabetes segment, which is expected to see a flurry of new product activity. While Soliqua has hit the market, all eyes are also on Novo Nordisk’s Awiqli and Cipla’s partnered inhaled insulin in the wings.
Asia Deal Watch: Nippon Shinyaku Takes On Intractable Rare Disease With MiNA
Plus deals involving Incyte/CMS, Biocytogen/ABL, Bharat/Biofabri/Bilthoven, Dr. Reddy’s/Pharmazz, Veeda/Heads, Sosei Heptares/GSK, BioGeometry/Sanyou, Ono/Sibylla and Teijin/BioProjet
Astellas CStO Pearson: We’re Not Short Of Opportunities To Compensate For LOEs
Astellas’ chief strategy officer, Adam Pearson, talks to Scrip about the company’s launch execution thrust for key therapies ahead of the loss of exclusivity for Xtandi and also deal-making appetite and choices, including the Iveric Bio buyout and walking away from the collaboration with Cartesian Therapeutics.